Mitochondrial Dysfunction Therapeutics
JanusQ is an early-stage company developing peptide-based therapies that target mitochondrial dysfunction in neurodegenerative diseases. With two lead peptides showing strong efficacy in animal models of Alzheimer’s and Huntington’s Diseases (AD and HD), we are well positioned to drive towards the clinic in pursuit of treatments for these debilitating and, ultimately, fatal diseases.
JQ1001 - Huntington's Disease
JQ1001 blocks a pathological interaction of the mutant huntingtin protein (mtHtt) with the mitochondrion, thereby preventing degradation of mitochondria and degeneration of neurons. The early intervention with JQ1001 in this cascade delays the onset of HD and extends the high-quality patient life.
JQ2001 - Alzheimer's Disease
JQ2001 prevents the pathological association of two mitochondrial proteins that, otherwise, would lead to mitochondrial fragmentation. Treatment with JQ2001 also improves brain cholesterol metabolism. The result is markedly improved behavioral and neurological outcomes, in both AD and HD.